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We recently identified a mutation in the I-kB kinase associated protein (IKBKAP) gene as the major cause of familial
dysautonomia (FD), a recessive sensory and autonomic neuropathy. This alteration, located at base pair 6 of the
intron 20 donor splice site, is present on 199.5% of FD chromosomes and results in tissue-specific skipping of
exon 20. A second FD mutation, a missense change in exon 19 (R696P), was seen in only four patients heterozygous
for the major mutation. Here, we have further characterized the consequences of the major mutation by examining
the ratio of wild-type to mutant (WT:MU) IKBKAP transcript in EBV-transformed lymphoblast lines, primary
fibroblasts, freshly collected blood samples, and postmortem tissues from patients with FD. We consistently found
that WT IKBKAP transcripts were present, albeit to varying extents, in all cell lines, blood, and postmortem FD
tissues. Further, a corresponding decrease in the level of WT protein is seen in FD cell lines and tissues. The WT:
MU ratio in cultured lymphoblasts varied with growth phase but not with serum concentration or inclusion of
antibiotics. Using both densitometry and real-time quantitative polymerase chain reaction, we found that relative
WT:MU IKBKAP RNA levels were highest in cultured patient lymphoblasts and lowest in postmortem central and
peripheral nervous tissues. These observations suggest that the relative inefficiency of WT IKBKAP mRNA pro-
duction from the mutant alleles in the nervous system underlies the selective degeneration of sensory and autonomic
neurons in FD.Therefore, exploration of methods to increase the WT:MU IKBKAP transcript ratio in the nervous
system offers a promising approach for developing an effective therapy for patients with FD.
Familial dysautonomia (FD, Riley-Day syndrome, hered-
itary sensory, and autonomic neuropathy type III [MIM
223900]) is an autosomal recessive disease that affects
the sensory and autonomic nervous systems. FD has a
remarkably high carrier frequency of 1 in 32 in the Ash-
kenazi Jewish population (Dong et al. 2002). In FD,
there is progressive depletion of unmyelinated sensory
and autonomic neurons (Pearson and Pytel 1978a, 1978b;
Pearson et al. 1978; Pearson 1979; Axelrod 1995). The
loss of neuronal function results in gastrointestinal dys-
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function, abnormal respiratory responses to hypoxic and
hypercarbic states, scoliosis, gastroesophageal reflux,
vomiting crises, lack of overflow tears, abnormal sweat-
ing, and postural hypotension (Riley et al. 1949; Axelrod
et al. 1974; Axelrod 1984). Recently, we and others iden-
tified a single noncoding mutation in the I-kB ki-
nase–associated protein (IKBKAP) gene that accounts
for 199.5% of all cases of FD (Anderson et al. 2001;
Slaugenhaupt et al. 2001). This major IKBKAP muta-
tion is a single-base change at base pair 6 of the donor
splice site of intron 20 (IVS206TrC). We found that this
mutation causes a decrease in splicing efficiency with
sporadic skipping of exon 20, thereby reducing the level
of WT IKBKAP mRNA in patient cells (Slaugenhaupt
et al. 2001). By contrast, data presented by Anderson
et al. (2001) suggested complete elimination of WT
IKBKAP mRNA in lymphoblast cells of patients with
FD. The only other mutation found in patients with FD
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to date is a rare missense alteration (R696P), existing
only in four patients heterozygous for the major splicing
mutation. It is located in exon 19 and is predicted to
disrupt a phosphorylation site in I-kB–associated protein
(IKAP), the IKBKAP gene product.
IKAP is a conserved protein found in mouse, fruitfly,
mustard plant, nematode, and yeast (Cuajungco et al.
2001). It was initially reported as a scaffold protein for
the I-kB kinase (IKK) complex (Cohen et al. 1998),
but this function was subsequently contested by Kra-
ppmann et al. (2000), who reported that IKAP was, in
fact, a member of a different cellular complex. IKAP is
now recognized as the largest member of the three-sub-
unit protein complex called “core Elongator,”whichwas
originally identified in yeast and, more recently, in hu-
mans (Otero et al. 1999; Wittschieben et al. 1999; Fel-
lows et al. 2000; Hawkes et al. 2002; Kim et al. 2002).
Studies in yeast and human have revealed that core Elon-
gator interacts with another three-subunit protein to
form the six-subunit holo-Elongator complex (Krogan
and Greenblatt 2001; Li et al. 2001; Winkler et al. 2001,
2002; Hawkes et al. 2002). Initial investigations in yeast
have suggested that core Elongator plays a role in tran-
scription elongation because of its observed histone ace-
tyl transferase activity, its observed interaction with na-
ked or nucleosomal DNA, as well as its interaction with
the hyperphosphorylated C-terminal domain of elon-
gating RNA polymerase II during transcription in vitro
(Otero et al. 1999; Winkler et al. 2001). Using purified
human core Elongator complex from HeLa cell extracts,
Kim and colleagues (2002) demonstrated that core Elon-
gator indeed facilitates transcription by RNA polymer-
ase II in a chromatin- and acetyl-coA-dependentmanner.
However, recent findings in yeast have called previous
observations into question. For example, when chromatin
immunoprecipitation assay was used, no evidence was
observed to suggest that yeast Elongator is directly in-
volved in transcription elongation in vivo (Pokholok et
al. 2002) or in vitro (Krogan et al. 2002). Likewise, using
tandem affinity purification, Krogan et al. (2002) failed
to copurify yeast Elongator with RNA polymerase II,
even at microgram quantities. It is interesting that im-
munofluorescence localization studies show that each
core Elongator subunit, including IKAP, is primarily de-
tected in the cytoplasm of human (Krappmann et al.
2000; Hawkes et al. 2002; Holmberg et al. 2002; Kim
et al. 2002) or yeast cells (Pokholok et al. 2002). More
recently, Holmberg et al. (2002) reported a novel scaf-
folding role for IKAP in the c-Jun N-terminal kinase
(JNK) signal transduction pathway, owing to its dis-
cerned strong physical interaction with JNK and en-
hancement of JNK activation. These studies suggest that
IKAP may indeed have multiple roles in the cell, and it
remains to be determined how a decrease in cellular
IKBKAP causes the FD phenotype and why this phe-
notype displays tissue specificity.
The regulation of gene splicing (reviewed by Nissim-
Rafinia and Kerem [2002]) can potentially play an im-
portant role in inherited disorders, influencing phenotypic
parameters such as organ specificity, disease severity, and
age at onset. Splicing mutations that result in exon skip-
ping have been reported for many disorders, including
adrenoleukodystrophy, ataxia telangiectasia, Marfan
syndrome, cystic fibrosis, retinoblastoma, tuberous scle-
rosis, and neurofibromatosis (Mayer et al. 2000; Pagani
et al. 2000; Alonso et al. 2001; Birrell et al. 2001; Gui-
maraes et al. 2001; Guo et al. 2001; Nissim-Rafinia and
Kerem 2002). Often, these mutations are associatedwith
a milder disease phenotype, suggesting the persistence
of residual protein activity due to a low level of correctly
spliced mRNA. The remarkable features of FD are that
a single splicing mutation is responsible for virtually all
cases of the disease and that, in our hands, homozygous
mutant cultured cells are capable of producing substan-
tial amounts of WT IKBKAP mRNA and protein (Slau-
genhaupt et al. 2001). These observations suggest that
manipulation of splicing mechanisms could offer a route
to treating FD and other human disorders involving
splicing defects.
In view of the differences in the reported effects of the
major FD mutation on splicing of exon 20 (Anderson et
al. 2001; Slaugenhaupt et al. 2001), we have characterized
the defective IKBKAP splicing using both densitometry
and real-time quantitative PCR assays in patient cell lines,
freshly collected blood, and FD postmortem tissues. We
collected patient blood samples through the Dysauton-
omia Diagnostic and Treatment Center at New York
University Medical Center, with approval from by the
Institutional Review Boards of New York University
Medical Center, Massachusetts General Hospital, and
Harvard Medical School. For each patient, total RNA
was extracted, and a lymphoblast cell line was initiated.
We also used previously generated patient lymphoblast
and fibroblast lines, as well as additional FD cell lines,
purchased from the Coriell Mutant Cell Repository, for
comparative experiments. All cultured cells were prop-
agated in a standard 37C incubator at 85% humidity
and 5% CO2, with lymphoblast lines grown in RPMI-
1640 and primary fibroblasts inMinimum EssentialMe-
dium with Earle’s balanced salts. Both media were sup-
plemented with 2 mM L-glutamine and either 10%
(GUS lines), 15% (GM lines), or 20% (MIN lines) fetal
bovine serum (FBS) (Invitrogen). In some experiments,
lymphoblast lines were grown with or without 100 U/
mL penicillin, and 100 mg/mL streptomycin (Sigma).
Postmortem tissues were obtained from the Pathology
Department at New York UniversityMedical Center and
the University of Miami Brain and Tissue Bank for De-
velopmental Disorder.
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Figure 1 IKBKAP amplicon sizes and their corresponding PCR products. A schematic representation of the primer sets and Taqman
probes used to amplify either the WT or MU IKBKAP transcripts. PCR primers 19F–23R amplify both WT and MU bands. The real-time
QPCR primers designated “WT-F/R” (forward/reverse) or “MU-F/R,” with their matching dual-labeled Taqman probes, amplify WT and MU
transcripts, respectively. The position of WT-R primer in exon 20 was designed to specifically amplify only the WT message, whereas the MU-
F primer located at the junction of exons 19 and 21 will amplify only the MU message. The dual-labeled Taqman probes have a melting
temperature (Tm) of 7C–10C above the primer Tm for each amplicon. Primer and probe sequences were as follows: 19F: CCT GAG CAG
CAA TCA TGT G; 23R: TAC ATG GTC TTC GTG ACA TC; WT-F: GCA GCA ATC ATG TGT CCC A; WT-R: ACC AGG GCT CGA TGA
TGA A; WT Taqman probe: FAM-GTT CAC GGA TTG TCA CTG TTG TGC C-BHQ; MU-F: CAC AAA GCT TGT ATT ACA GAC T;
MU-R: GAA GGT TTC CAC ATT TCC AAG; and MU Taqman probe: FAM-CTC AAT CTG ATT TAT GAT CAT AAC CCT AAG GTG-
BHQ. The housekeeping gene 18S rRNA was used for normalization: 18S-F: GGC CCT GTA ATT GGA ATG AG; 18S-R: GCT ATT GGA
GCT GGA ATT AC; and 18S Taqman probe: FAM-TGC TGG CAC CAG ACT TGC CCT C-BHQ.
Total RNA was extracted using Tri-Reagent for all tis-
sues and cultured cell samples, or Tri-Reagent BD for
blood (Molecular Research Center), and quantitated by
UV absorbance. Reverse-transcription reactions using
oligo-dT15/random hexamer primers (Promega), Super-
script II reverse transcriptase (200 U/mL; Invitrogen) and
RNase-inhibitor (80 U/mL; Roche) were performed as
described (Cuajungco et al. 2001). PCR was done on all
samples to evaluate both WT and MU transcripts (fig.
1). The PCR products were fractionated by electropho-
resis on a 1.5% agarose gel stained with ethidium bro-
mide. Each gel band was assessed using an Alpha 2000
Image Analyzer and software coupled with automatic
background subtraction (Alpha Innotech). Subsequent
analysis of the integrated density value (IDV) to calculate
the WT:MU transcript ratio enabled us to obtain the
relative differences in expression within each patient tis-
sue or cell samples. To validate our densitometry find-
ings, we used real-time quantitative PCR (QPCR). For
QPCR, the 18S ribosomal RNA (Applied Biosystems)
was used as an internal normalization control to correct
for variations in input RNA amount or reverse tran-
scription efficiency. The 18S rRNA is known for its ro-
bustness and stable expression across different tissues
and cell lines (Schmittgen and Zakrajsek 2000; Goidin
et al. 2001). We used a One-Step RT-Platinum Taq kit
(Invitrogen), optimized to 5 mM Mg, with 500 nM
forward and reverse primers, 400 nM TaqMan probe,
and 200 ng of total RNA sample. QPCR was done on
a BioRad thermal ICycler with the following PCR pro-
gram: 1 cycle at 50C for 15 min; 1 cycle at 95C for 5
min; and 45 cycles at 95C for 15 sec, and at 59 C for
1 min. All reactions were carried out in triplicate in a
96-well plate format, with a final volume of 50 mL. Trials
for each WT, MU, or 18S assay included four duplicated
tissue samples and “no RT” controls. For relative gene-
expression analysis, we used the standard curve method
(generated from the same serial dilutions of MIN9741
752 Am. J. Hum. Genet. 72:749–758, 2003
Figure 2 A, Expression of WT andMU IKBKAPmRNA in various lymphoblast cell lines of patients with FD. A total of 81 FD lymphoblast
cell lines were assayed, using a densitometric assay. Representative samples are shown, including the GM5106 (Coriell) sample used by Anderson
et al. (2001). All FD lines consistently expressed both WT IKBKAP (upper band, lane 1–lane 10) and MU (lower band, lane 1–lane 10). Note
that MU IKBKAP transcript is never detected in RNA from normal cells or tissues (lane 11–lane 12). Lp100-bp ladder; 1pFD (MIN9741,
new line); 2pFD (MIN9744, new line); 3pFD (MIN9741, new line); 4pCarrier (GM5105, Coriell); 5pFD (GM5107, Coriell); 6pFD
(GM5106, Coriell); 7pFD (GM5106, established line); 8pFD (GM5041, established line); 9pFD (GUS13131, established line); 10pFD
(GUS14939, established line); 11pnon-FD control (GM5043, Coriell); and 12pnon-FD control (GM5110, Coriell). WT amplicon sizep363
bp; MU amplicon sizep289 bp. B, Expression of WT and MU IKBKAP mRNA in postmortem FD tissue samples and cell lines. All samples
were assayed and analyzed as described in our methodology. The relative WT:MU transcript ratio was consistently observed to be highest in
FD lymphoblast lines, lowest in FD nervous system tissues, and intermediate in other tissues. The distinctive reduction of relative WT message
in most of the CNS and PNS tissues corresponds to the tissue-specific pathology observed among patients with FD.
lymphoblast sample used in every plate run) to correct
for minor differences in PCR efficiency (Heid et al. 1996;
Winer et al. 1999; Giulietti et al. 2001). QPCR values
were expressed relative to an FD spleen sample that
showed virtually equalWT andMU IKBKAP expression
and was included as a calibrator in every experimental
run. For protein analysis, available FD postmortem tis-
sues and cell lines were homogenized and total protein
quantitated by use of bicinchoninic assay (Pierce). For
each sample, 400 mg of total protein was run on a 6%
denaturing polyacrylamide gel and Western blotted. The
blots were probed using an anti-IKAP C-terminal poly-
clonal antibody (a kind gift from Dr. Jesper Svejstrup
and Dr. Claus Schedereit) and the protein detected by
ECL (Amersham), as described elsewhere (Slaugenhaupt
et al. 2001). The polyvinylidene fluoride membrane was
stained for total protein, using 0.2% Ponceau-S (Sigma)
to confirm equal loading and transfer.
Our original report (Slaugenhaupt et al. 2001) sug-
gested that lymphoblast cell lines from patients with FD
were capable of expressingWT IKBKAP transcript from
the mutant FD allele. These data contrasted with the
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Table 1
Quantitative Analysis of WT and MU IKBKAP Expression Ratio in Cultured Cells
HARVEST
EXPRESSION RATIO IN LYMPHOBLAST CELL LINE
MEANSDMIN9741 MIN9744 MIN9745 MIN9754
1 3.00 3.52 2.55 3.19 3.070.41
2 2.86 2.18 3.00 2.51 2.640.37
3 2.70 2.15 2.17 2.60 2.410.29
4 4.50 3.60 4.47 5.13 4.430.63
5 4.00 4.14 3.78 4.36 4.070.24
6 2.09 2.22 1.90 2.28 2.120.17
7 2.53 2.33 2.71 2.26 2.460.20
8 3.57 3.81 3.62 3.64 3.660.10
9 3.69 3.88 3.33 3.19 3.520.32
10 3.65 3.67 3.39 2.84 3.390.39
11 3.03 3.71 2.71 2.93 3.090.43
12 2.21 2.97 2.53 4.18 2.970.86
13 2.78 3.52 2.97 2.84 3.030.34
14 2.82 3.30 3.77 3.00 3.220.41
MeanSD 3.100.69 3.210.71 3.060.70 3.210.84
NOTE.—We assayed four independent lymphoblast lines over 14 harvest periods. The
cells were harvested at saturation phase (every 7th d) and assayed using densitometry
for WT:MU expression ratio, as described. The results showed that, over the cultured
time period assessed, no significant difference existed between cell lines ( ). A sig-Np 4
nificant difference, however, was observed between harvest times , ).(P ! .0001 Np 14
absence of WT transcript in FD lymphoblast cells in the
report of Anderson et al. (2001). To address this dis-
crepancy, we obtained the GM5106 FD cell line used by
Anderson et al. from the Coriell Mutant Cell Repository
and compared it with a frozen GM5106 stock already
present in our laboratory, as well as with independent
lymphoblast cell lines from other patients homozygous
for the major mutation. We employed densitometry as
a rapid assay to characterize the relative WT:MU tran-
script ratio of 81 FD lymphoblast cell lines. Of these
samples, we consistently found significant WT IKBKAP
mRNA in all FD cell lines examined (fig. 2A), including
that of the patient sample tested by Anderson et al.
(2001) (see lane 6 and lane 7 in fig. 2A).
To assess whether the efficiency of accurate IKBKAP
splicing might vary over time, we used four independent
lymphoblast cell lines (MIN9741,MIN9744,MIN9745,
and MIN9754) from patients with FD who were homo-
zygous for the major mutation. The cells were cultured
and assayed weekly for 14 wk (fed every 3 d and har-
vested on the 7th d at saturation density of ∼20 million
cells). The cell lines did not differ significantly in their
overall average WT:MU IDV ratio for the entire culture
period (table 1). However, the ratio did show significant
fluctuation ( ), over a twofold range betweenP ! .0001
harvests, with the relative levels of expression seeming
to vary in concert in different cell lines. This suggests
that uncontrolled variability in the conditions of culture
or harvesting shared by all four cell lines operated to
modify the relative efficiency of IKBKAP splicing to
some degree.
We performed several experiments to vary specific as-
pects of the culture conditions to determine whether they
had an impact on the WT:MU ratio. We first tested
whether culturing lymphoblast lines with or without the
common media antibiotic additives (penicillin/strep-
tomycin) would influence WT:MU IKBKAP ratio, as
there was a recent report that pre-mRNA splicing in
vitro is inhibited by certain antibiotics (Hertweck et al.
2002). Three different FD lymphoblast lines were grown
and harvested every 7th d at saturation density, as above.
After assaying for a period of 4 wk, no significant dif-
ference was seen in mean WT:MU expression ratios be-
tween the respective treated and nontreated cell lines,
either at individual harvests or in the average of all har-
vests (data not shown).
Next, we investigated the effects of changing the per-
centage of supplemented FBS on lymphoblast lines using
10 independent cell lines. Five of these (MIN lines) were
initiated and maintained in 20% FBS, whereas the other
five (GUS lines) had been adapted in long-term culture to
10% FBS. Each of the 10 lines was split into two match-
ing cultures, one at 20% FBS and one at 10% FBS. These
matching cultures were maintained at their respective
FBS levels throughout the experiment and were har-
vested twice in logarithmic growth and twice at satu-
ration. No significant difference in WT:MU ratio was
seen between cultures grown consistently at 10% FBS
and their matching cultures increased to 20% FBS
(2.320.74 vs. 2.290.62) between cultures grown
consistently at 20% FBS and their matching count-
erparts decreased to 10% FBS (3.230.97 vs.
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Table 2







MEANSDA B C D
MIN9744:
1 2.15 1.81 200 181 1.940.16
2 2.18 2.09 2.14 1.97 2.090.09
3 2.93 2.94 3.00 2.89 2.940.05
4 4.21 3.50 3.67 3.78 3.790.30
Mean 2.87 2.59 2.70 2.61
Overall 2.690.78
GUS14939:
1 1.46 1.47 1.45 1.56 1.490.05
2 2.75 271 2.90 2.80 2.790.08
3 2.19 1.90 2.00 2.00 2.020.12
4 2.67 2.22 2.81 2.18 2.470.32
Mean 2.27 2.08 2.29 2.14
Overall 2.190.53
MIN9754:
1 3.14 2.63 3.26 3.07 3.030.27
2 4.10 3.72 3.56 2.39 3.890.30
3 3.80 3.27 3.67 2.48 3.540.24
4 3.21 2.39 3.41 2.42 2.630.39
Mean 3.56 3.00 3.24 3.27
Overall 3.270.57
GUS28025:
1 2.96 1.59 1.86 1.79 2.050.62
2 2.49 1.94 2.50 2.53 2.370.28
3 3.56 3.38 3.39 3.44 3.440.08
4 2.42 1.97 2.11 2.58 2.270.28
Mean 2.86 2.22 2.47 2.59
Overall 2.530.65
NOTE.—Four independent FD lymphoblast cell lines were
cultured over 4 wk to assess the consistency of WT:MU ex-
pression ratio in each individual cell line. Each cell line was
split into four parallel cultures and assayed using densitometry
as described.
3.151.01), or between all cultures grown at 10% FBS
versus 20% FBS (2.730.98 vs. 2.760.94). However,
although the FBS content did not alter the WT:MU ra-
tio, this parameter was significantly affected by the state
of the cultures at harvest, as the relative amount of
WT IKBKAP RNA was higher in saturated cultures
(3.220.93) than in logarithmically growing cultures
( ) ( ). It is not clear why or how2.27 0.64 P ! .0005
high cell density can apparently influence IKBKAP
expression.
Our findings indicate that theWT:MU ratio in a given
FD cell line can fluctuate because of culture conditions,
implying that the efficiency of producing accurately
spliced RNA from the mutant allele can be altered. In
these experiments, we have eliminated some obvious po-
tential sources of variation, such as antibiotic treatment
and FBS concentration, and implicated an effect of cell
density/growth state. However, the fact that the capacity
of the mutant allele to be spliced accurately can be mod-
ified by as-yet-uncertain external signals provides the
proof of principle to search for chemical compounds that
can increase the WT:MU IKBKAP ratio and therefore
have potential for therapeutic use in FD. The ability to
use FD cells to screen for such compounds depends on
the degree to which parallel cultures of the test cell line
display equivalent WT:MU ratios. We investigated con-
sistency of expression within cell lines, by splitting four
independent FD lymphoblast lines into four parallel cul-
tures each and harvesting these four times over a period
of 4 wk. Although the independent cell lines showed
different WT:MU ratios relative to each other and fluc-
tuated in WT:MU ratio between harvests, replicate cul-
tures of the same line typically yielded very consistent
WT:MU IKBKAP expression ratios at any given harvest
(table 2). Thus, although the relative efficiency of
IKBKAP splicing can vary between independent cell
lines and between harvests, multiple replicates of the
same culture harvested at the same time yield very small
SDs in the mean WT:MU ratios (SD range 0.05–0.62).
This suggests that FD mutant cells, assayed simulta-
neously as multiple parallel cultures diluted from a single
source culture, offer a viable route for screening to iden-
tify compounds that alter the WT:MU IKBKAP ratio.
To date, we have also assayed three distinct primary
fibroblast lines from patients with FD, and we also con-
sistently observed the presence of both WT and MU
IKBKAP messages in this cell type. It is interesting that
cultured primary fibroblast cells harvested either at high
(∼90%–100% confluence) or low cell density (∼50%–
60% confluence) give relatively lower WT:MU ratio of
1.210.20 and 1.850.85, respectively, than that of
cultured lymphoblasts (see also table 3), suggesting an
inherent cell-type difference in the efficiency of accurate
splicing from the mutant allele.
To determine whether the capacity to produce WT
transcript from the mutant FD allele reflects the artificial
state of cells in culture, we assayed several fresh blood
samples taken from patients. We consistently found ex-
pression of WT and MU transcripts from the mutant
alleles, indicating that FD cells indeed produce WT
IKBKAP transcript in vivo (WT:M ,Up 1.46 0.08
).Wewent on to assay postmortemFD tissues fromNp 4
different CNS and peripheral nervous system (PNS)
regions, as well as from other available organs. The re-
sults of densitometric assays of these tissues showed that
MU IKBKAP transcripts predominate in both the CNS
and PNS (fig. 2B). The densitometry data on nervous
system tissues gave a WT:MU transcript ratio of !1.0,
whereas patient lymphoblast lines gave a consistent ratio
11.0 (table 3). These observations were confirmed using
real-time QPCR (table 3; fig. 3). Lymphoblast cell lines
from patients with FD displayed relatively high levels of
WT IKBKAP transcript, followed by tonsil, spleen, and
intercostal nerve, whereas other organs showed rela-
Figure 3 Graphical representation of relative WT and MU IKBKAP expression levels in various FD postmortem tissues and cultured cell
lines, measured by use of real-time QPCR. The QPCR values were normalized using 18S rRNA, and the spleen tissue was used as the calibrator
for relative comparisons between patient samples. A, Relative WT IKBKAP levels. The FD lymphoblast cell lines followed by the tonsil tissue
showed relatively higher levels of WT message than any other patient tissues examined. B, Relative mutant IKBKAP levels. Several areas of
the neocortex, as well as the brain stem medulla, striatum (caudate nucleus), spinal cord, and intercostal nerve tissue samples, showed relatively
higher levels of the MU IKBKAP transcript compared with other patient tissues and cell lines investigated. Among the nonnervous tissues tested,
only the tonsil, esophagus, and one of the lung samples (case B) showed relatively high MU IKBKAP levels, whereas the others had intermediate
levels.
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Table 3
Densitometric and Real-Time QPCR Analyses of





Temporal cortex .35 .35
Medulla oblongata .29 .27
Spinal cord .25 .43
Sympathetic chain .24 .19









Skeletal muscle .68 .94
Fibroblast 1.33 1.01
Lymphoblast 3.53 3.44
NOTE.—TheWT:MU IKBKAP ratio was calculated from data
obtained by densitometry and real-time QPCR, using sample
tissues represented in figure 2B. Results from the densitometric
technique showed very high concordance with real-time QPCR
values. The WT:MU data for both CNS and PNS tissues con-
sistently produced a ratio !1.0, whereas cultured cells (lym-
phoblast and fibroblast) consistently yielded a ratio 11.0. QPCR
values were expressed relative to the spleen as calibrator for
both WT and MU levels, as described.
Figure 4 Western blot showing relative IKAP expression levels
in FD postmortem tissues and cultured cell lines. Protein was extracted
from several cell lines and postmortem tissues, as shown, and was run
on 6% denaturing polyacrylamide gel. The samples were transferred
to a PVDF membrane and stained with Ponceau-S to confirm equal
protein loading. IKAP was detected using a C-terminal polyclonal an-
tibody. Here, we show that IKAP levels are reduced in the FD lympho-
blast and fibroblast samples compared with controls, and IKAP is
either absent or below the level of antibody detection in FD brain
tissues.
tively intermediate WT levels (fig. 3A). By contrast, rel-
ative MU IKBKAP message varied markedly between
different CNS and PNS regions, with higher MU levels
observed in the brain stem (medulla oblongata), striatum
(caudate nucleus), neocortex (frontal, temporal, parietal,
and occipital), spinal cord, and intercostal nerve (figs.
2B and 3B). The tonsil, esophagus, and lung tissue sam-
ples are among the only nonnervous organs that showed
relatively highMU expression. The presence of relatively
more MU transcript in various CNS and PNS regions
indicates that IKBKAP-splicing efficiency is distinctly af-
fected by the FD gene defect in these tissues. These data
also suggest that the identity and relative amounts of
cellular splicing factors involved in the correct splicing
of IKBKAP may vary from tissue to tissue, with certain
neuronal cells, including those in the sensory and auto-
nomic nervous systems, being particularly susceptible to
missplicing in FD.
The fact that FD is recessive, with no phenotype in
carriers, coupled with the fact that patient cells are ca-
pable of producing normal message and protein, pres-
ents an exciting possible approach to treatment. By tar-
geting the splicing pathway, it may be possible to increase
the level of normal IKAP protein in FD cells. This ap-
proach has recently shown promise for the treatment of
spinal muscular atrophy (SMA), another neurodegener-
ative disorder. SMA is caused by loss of function mu-
tations in the SMN1 gene. A nearly identical SMN2 gene
encodes transcripts that are missing exon 7 because of
a mutation that disrupts an exonic splice enhancer.How-
ever, it has been shown that SMN2 encodes a small
amount of full-length mRNA, the amount of which is
inversely correlated with SMA disease severity, because
it compensates for the absent SMN1 protein. Recent
studies have shown that SMN2 mRNA processing can
be modulated in vitro and in vivo by both splicing factors
and drugs, offering a potential for the treatment of SMA
in humans (Hofmann et al. 2000; Andreassi et al. 2001;
Chang et al. 2001). Although the exon-skipping mech-
anism in SMA is different from that in FD, these ob-
servations clearly demonstrate that certain drugs, or
other transacting factors, have the potential to preclude
skipping of exon 20 in IKBKAP.
To confirm that the observed change in IKBKAP
mRNA expression results in a corresponding decrease
in IKAP protein, we performed a Western blot analysis
using an anti-IKAP C-terminal antibody (Slaugenhaupt
Reports 757
et al. 2001) (fig. 4). As expected, there is a reduction in
IKAP protein in both the FD lymphoblast and FD fibro-
blast samples, and no IKAP was detected in the FD brain
postmortem tissues available for study. This observation
confirms that the significant reduction of WT IKBKAP
mRNA in FD nervous tissue leads to either a complete
absence of normal IKAP or reduction of the protein to
an undetectable level.
In conclusion, our data demonstrate that all FD cell
types examined are capable of producing WT IKBKAP
transcripts from the mutant FD alleles, regardless of the
tissue source or culture conditions. However, the relative
efficiency of accurate splicing varies dramatically, with
nervous system tissues displaying the lowest relative
amounts of WT IKBKAP transcript. This is consistent
with FD being caused not by the absence of IKAP per se
but by its reduction below critical levels in sensory and
autonomic neurons. Most importantly, the fact that the
FDmutation does not fully obliterate splicing, but rather
results in a tissue-specific decrease in WT IKBKAP
mRNA levels, provides an exciting avenue for ther-
apeutic exploration. This result provides a basis for
the identification of cellular splicing modulators, such
as drugs and/or splicing factors that enhance the effi-
ciency of inclusion of exon 20 in IKBKAP transcripts
from mutant alleles. Indeed, a crucial by-product of our
studies is the definition of quantifiable baselines of ex-
pression, for both WT andMU IKBKAP transcripts from
patient cell lines, that can be employed for future drug
screening, to identify compounds with therapeutic poten-
tial for patients with FD.
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